{"id":501,"date":"2025-03-13T14:53:08","date_gmt":"2025-03-13T14:53:08","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=501"},"modified":"2026-02-09T12:36:08","modified_gmt":"2026-02-09T12:36:08","slug":"ffboost","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=501","title":{"rendered":"FFBoost"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

FAST-Forward BOOST: A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost (SIB) radiotherapy against a standard 3-week schedule in patients with early breast cancer.<\/strong><\/h2>\n\n\n\n
Trial Summary:<\/strong><\/h5>\n\n\n\n

The FAST-Forward Boost trial is a Phase III multicentre randomised controlled study investigating a one-week schedule of simultaneous integrated boost (SIB) radiotherapy against the standard three-week schedule in patients with early breast cancer requiring radiotherapy. The trial aims to determine whether the shorter treatment course is non-inferior in terms of local recurrence rates while evaluating its impact on acute toxicity, late effects, quality of life, and health economics. The study will enrol participants, randomised in a 1:1:1 ratio to receive either standard three-week SIB radiotherapy (48Gy in 15 fractions), or one of two one-week SIB regimens (31Gy or 30Gy in 5 fractions). Primary endpoint analysis will assess ipsilateral breast tumour recurrence at five years, while secondary outcomes include patient-reported symptoms, clinician-reported adverse events, recurrence-free survival, Breast cancer-related survival, Health economics<\/em> and overall survival. An early side-effects sub-study will focus on acute toxicity, particularly skin reactions, and a health economics evaluation will assess treatment cost-effectiveness. Follow-up will continue for at least five years, with additional analysis of long-term outcomes through healthcare datasets. This trial aims to establish shorter, more convenient radiotherapy regimens while maintaining efficacy and safety.<\/em><\/p>\n\n\n\n

RT QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>Specific Case for all RT Centres<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>Specific Case for all RT Centres<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective: 1st IMC and 1st Non-IMC Plan for each treatment centre
\n
\nRetrospective: 1 in every 10 treatment plans from each centre up to a maximum of 5 plans.<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td><\/td>\n<\/tr>\n
Dosimetry Audit<\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td>\"\"<\/td>PARABLE, ATNEC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact: <\/strong>enh-tr.ffboostqa@nhs.net<\/a><\/p>\n\n\n\n

Chief Investigator:<\/strong> Dr Anna Kirby<\/p>\n\n\n\n

RT Lead:<\/strong> Dr Carmel Anandadas<\/p>\n\n\n\n

Sponsor:<\/strong> The Institute of Cancer Research (fastforwardboost-icrctsu@icr.ac.uk<\/a>)<\/p>\n\n\n\n

Funder: <\/strong>National Institute for Health and Care Research (NIHR) \u2013 Health Technology Assessment (HTA) Programme<\/p>\n\n\n\n

FAST-Forward Boost study page: <\/strong>Fast-Forward Boost study<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

FAST-Forward BOOST: A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost (SIB) radiotherapy against a standard 3-week schedule […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-501","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=501"}],"version-history":[{"count":2,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/501\/revisions"}],"predecessor-version":[{"id":530,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/501\/revisions\/530"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}